Literature DB >> 31375202

Precision Medicine for Idiopathic Hypersomnia.

Isabelle Arnulf1, Smaranda Leu-Semenescu2, Pauline Dodet2.   

Abstract

Idiopathic hypersomnia (IH) is characterized by excessive daytime sleepiness despite normal or prolonged sleep. IH is distinguished from narcolepsy by the female predominance, severe morning inertia, continuous drowsiness (rather than sleep attacks), unrefreshing naps, absence of cataplexy, sleep onset in REM periods, and hypocretin deficiency. In IH, the multiple sleep latency test demonstrates low sensitivity, specificity, and reproducibility, compared with prolonged sleep monitoring. In some IH cases, an endogenous hypnotic peptide stimulating GABA receptors during wakefulness is suspected, which are improved by anti-GABA drugs. The benefits of modafinil, sodium oxybate, mazindol, and pitolisant were found in mostly retrospective studies.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drowsiness; GABA; Hypersomnia; Long sleep time; Modafinil; Sodium oxybate

Year:  2019        PMID: 31375202     DOI: 10.1016/j.jsmc.2019.05.007

Source DB:  PubMed          Journal:  Sleep Med Clin        ISSN: 1556-407X


  7 in total

1.  The melanopsin-mediated pupil response is reduced in idiopathic hypersomnia with long sleep time.

Authors:  Héloïse Rach; Ulker Kilic-Huck; Eve Reynaud; Laurence Hugueny; Emilie Peiffer; Virginie Roy de Belleplaine; Fanny Fuchs; Patrice Bourgin; Pierre A Geoffroy
Journal:  Sci Rep       Date:  2022-05-30       Impact factor: 4.996

2.  Stability of nocturnal wake and sleep stages defines central nervous system disorders of hypersomnolence.

Authors:  Kiran P Maski; Alicia Colclasure; Elaina Little; Erin Steinhart; Thomas E Scammell; William Navidi; Cecilia Diniz Behn
Journal:  Sleep       Date:  2021-07-09       Impact factor: 6.313

3.  Evaluation of pathological sleepiness by Multiple Sleep Latency Test and 24-hour polysomnography in patients suspected of idiopathic hypersomnia.

Authors:  Makoto Honda; Shinya Kimura; Kaori Sasaki; Masataka Wada; Wakako Ito
Journal:  Psychiatry Clin Neurosci       Date:  2021-02-13       Impact factor: 5.188

4.  Epigenetics of Sleep Disorders: An Emerging Field in Diagnosis and Therapeutics.

Authors:  Rene Cortese
Journal:  Diagnostics (Basel)       Date:  2021-05-10

5.  The dual orexin receptor antagonist almorexant blocks the sleep-disrupting and daytime stimulant effects of methamphetamine in rhesus monkeys.

Authors:  Lais F Berro; Eliseu da Cruz Moreira-Junior; James K Rowlett
Journal:  Drug Alcohol Depend       Date:  2021-07-28       Impact factor: 4.852

6.  Validation of the Colombian version of the Karolinska sleepiness scale.

Authors:  María Camila Laverde-López; Franklin Escobar-Córdoba; Javier Eslava-Schmalbach
Journal:  Sleep Sci       Date:  2022 Jan-Mar

7.  Treatment of severe morning sleep inertia with bedtime long-acting bupropion and/or long-acting methylphenidate in a series of 4 patients.

Authors:  Carlos H Schenck; Erin C Golden; Richard P Millman
Journal:  J Clin Sleep Med       Date:  2021-04-01       Impact factor: 4.062

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.